Breakthrough Gene-Editing Therapy Approved for Beta-Thalassemia Treatment

Finally, after intense anticipation, Vertex Pharmaceuticals (NASDAQ:VRTX) has triumphed as the U.S. FDA has granted its trailblazing gene editing therapy, Casgevy, developed in partnership with CRISPR Therapeutics (NASDAQ:CRSP), approval for individuals aged 12 years and older with transfusion-dependent beta-thalassemia (TDT).

Coming on the heels of the regulatory body’s consent for Casgevy in the treatment of sickle cell disease, marking it as the inaugural gene editing therapy sanctioned in the United States, this milestone is a testament to the relentless commitment to innovation and sound science.

Casgevy, a revolutionary CRISPR/Cas9 gene-edited cell therapy, had been under stringent evaluation by the FDA for TDT, with a target action date initially set for March 30.

“On the heels of the historic FDA approval of CASGEVY for sickle cell disease, it is exciting to now secure approval for TDT well ahead of the PDUFA date,” Reshma Kewalramani, CEO of Vertex (VRTX), remarked, exuding confidence in the company’s pioneering strides.

The company has also disclosed that nine clinical centers across the U.S. have now been granted authorization to administer Casgevy to TDT patients, with plans for additional sites to be rolled out in the coming weeks. According to Boston Children’s Hospital, there are at least 1,200 patients with TDT in the US.